Combining Exothera’s development and manufacturing expertise with Quantoom’s continuous biomanufacturing platform will allow biotech and pharma companies to simplify RNA vaccine development and accelerate their clinical and commercial timelines. By leveraging the Nfinity technology, Exothera will offer development services, non GMP and GMP manufacturing as well as analytical services to pharma/biotech for mRNA and saRNA therapeutic development.
Thibault Jonckheere, CEO of Exothera, commented: “The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialization. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences. This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible.”
Exothera’s services will be available to biotech and pharmaceutical companies of all sizes and stages of development whether they are starting from a known protein sequence (antigen) or have a product in pre-clinical development or clinical trials. The company is currently accepting inquiries for its services and is actively seeking partnerships with biotech and pharmaceutical companies to support their drug development programmes.